Windtree Therapeutics (WINT) announces that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences (EVFM) for one of Evofem’s FDA-approved products — PHEXXI. The product is a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. PHEXXI annual revenues have grown to more than $19 million with more than 96,000 boxes of 12 pre-filled applicators sold in full year 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics announces notice of allowance from USPTO for istaroxime
- Windtree Therapeutics files patent in India for cardiac arrythmia therapy
- Windtree Therapeutics Inc trading halted, news pending
- Windtree Therapeutics Announces Reverse Stock Split Approval
- Windtree Therapeutics board approves 1-for-50 reverse stock split